Insight
Francesco Schettini
Photo taken from Francesco Schettini/X

Evolution of HR+/HER2- breast cancer during exposure to neoadjuvant chemotherapy and endocrine treatment

ESMO Open shared a post on X:

“Hot off the press: Francesco Schettini et al. analyze the clinical and biological evolution of HR+/HER2- breast cancer during exposure to neoadjuvant chemotherapy and endocrine treatment. ”

Image

Proceed to the article.
Source: ESMO Open/X

 

cancer endocrine treatment ESMO Open Francesco Schettini HR+/HER2- breast cancer neoadjuvant chemotherapy OncoDaily Oncology